- ►juanncorpas.edu.co [PDF] DE DeWitt, IB Hirsch - Jama, 2003 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do to make
your experience on this site better. ... Context Newer insulin therapies, including the ... Cited by 273 - Related articles - BL Direct - All 8 versions
J Pickup, H Keen - Diabetes care, 2002 - Am Diabetes Assoc Continuous subcutaneous insulin infusion (CSII) is used in selected type 1 diabetic subjects
to achieve strict blood glucose control. A quarter of a century after its introduction, world-wide
use of CSII is increasing. We review the evidence base that justifies this increase, ... Cited by 225 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org B Bode, R Weinstein, D Bell, J McGill, D Nadeau, P … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—Treatment groups had similar baseline HbA 1c (7.3% ±0.7 for IAsp, 7.5% ±0.8 for
BR, and 7.3% ±0.7 for lispro). After 16 weeks of treatment, HbA 1c values were relatively unchanged
from baseline, and the mean changes in baseline HbA 1c values were not significantly ... Cited by 122 - Related articles - BL Direct - All 20 versions
J Plank, A Siebenhofer, A Berghold, K Jeitler, K … - Archives of Internal …, 2005 - Am Med Assoc Results Forty-two randomized controlled trials that assessed the effect of SAI analogues vs regular
insulin in 7933 patients with type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational
diabetes mellitus were identified. The weighted mean difference between hemoglobin A ... Cited by 80 - Related articles - BL Direct - All 5 versions
JH DeVries, FJ Snoek, PJ Kostense, N Masurel, RJ … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—As the drop-out rate after crossover was high (17 of 79 patients [22%]), we analyzed
the trial as a parallel clinical trial, using data of the first half of the crossover phase only. At 16
weeks, mean HbA 1c was 0.84% (95% CI −1.31 to −0.36) lower in the continuous ... Cited by 77 - Related articles - BL Direct - All 6 versions
T Danne, J Aman, E Schober, D Deiss, JL … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glycemic control for postprandial treatment was not worse than preprandial treatment
as assessed by fructosamine week 0 vs. 6 (mean ± SD, preprandial 367 ± 74 vs. 378 ± 90
μmol/l; postprandial 383 ± 83 vs. 385 ± 77 μmol/l) and HbA 1c (preprandial 7.9 ± 1.3 vs. ... Cited by 63 - Related articles - BL Direct - All 7 versions
- ►adisonline.com [PDF] R Oiknine, M Bernbaum, AD Mooradian - Drugs, 2005 - pt.wkhealth.com Insulin is one of the oldest and best studied treatments for diabetes mellitus. Despite many improvements
in the management of diabetes, the nonphysiological time-action profiles of conventional insulins
remain a significant obstacle. However, the advent of recombinant DNA technology made ... Cited by 60 - Related articles - All 5 versions
A Lindholm - Best Practice & Research Clinical Gastroenterology, 2002 - Elsevier Landmark studies have confirmed the importance of intensified insulin treatment for minimizing
long-term diabetic complications. Human insulin is still first-line treatment. However, even the
most intensive of human insulin-based regimens can only poorly reproduce ... Cited by 53 - Related articles - BL Direct - All 8 versions
RP Radermecker, AJ Scheen - Diabetes/Metabolism Reviews - interscience.wiley.com Portable insulin infusion devices are effective and safe insulin delivery systems for managing
diabetes mellitus, especially type 1 diabetes. Rapidly absorbed insulin analogues, such as insulin
lispro or insulin aspart, may offer an advantage over regular human insulin for insulin ... Cited by 50 - Related articles - BL Direct - All 3 versions
